Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy

The Eighth Edition <scp>AJCC</scp> Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging

Mahul B. Amin, Frederick L. Greene, Stephen B. Edge et al. · CA A Cancer Journal for Clinicians · 2017 · 6.3K citations · Full text

Surgical Oncology, Cancer Pathology, Cancer Management +17

Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer

Nicholas D. James, Syed A. Hussain, Emma Hall et al. · New England Journal of Medicine · 2012 · 925 citations · Full text

Long-Term Outcomes in Patients With Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233

Raymond H. Mak, Daniel Hunt, William U. Shipley et al. · Journal of Clinical Oncology · 2014 · 438 citations · Full text

Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience

Nicholas J. Giacalone, William U. Shipley, R.H. Clayman et al. · European Urology · 2017 · 390 citations

Urological Research, Urology, Surgical Oncology +9

Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer

Rachel Howard, Peter A. Kanetsky, Kathleen M. Egan · Scientific Reports · 2019 · 285 citations · Full text